Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Bull and bear on a tablet_Image by Ice stocker via Shutterstock
Wall Street Doubles Down on Wolfspeed Short Positions Over Cash Burn Fears Barchart - Wed Jul 8, 9:00AM CDT

WOLF is now Wall Street's most shorted stock. Here's why bears keep piling on even after Wolfspeed's big debt overhaul.

SOUN : 6.65 (-0.45%)
RNECY : 14.9600 (-1.45%)
WOLF : 35.65 (-4.30%)
NTLA : 14.57 (-5.63%)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Jul 6, 3:05PM CDT

CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 14.57 (-5.63%)
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema GlobeNewswire - Sat Jun 13, 6:30AM CDT

Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026 HAELO manuscript simultaneously published...

NTLA : 14.57 (-5.63%)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Jun 5, 3:05PM CDT

CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 14.57 (-5.63%)
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026 GlobeNewswire - Mon Jun 1, 6:30AM CDT

CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 14.57 (-5.63%)
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates GlobeNewswire - Mon May 11, 6:30AM CDT

Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027 Recently resumed patient screening in MAGNITUDE...

NTLA : 14.57 (-5.63%)
Image of Cathie Wood via Wikimedia Commons
Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs but Cathie Wood Keeps Buying Barchart - Tue May 5, 1:05PM CDT

Despite Intellia's severe stock drop from its 2021 peak, Cathie Wood is buying big.

ARKG : 41.31 (-3.93%)
REGN : 663.96 (-0.60%)
NTLA : 14.57 (-5.63%)
ARKK : 80.48 (-1.29%)
Intellia Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire - Tue May 5, 6:30AM CDT

CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 14.57 (-5.63%)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri May 1, 3:01PM CDT

CAMBRIDGE, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 14.57 (-5.63%)
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire - Wed Apr 29, 6:00AM CDT

CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 14.57 (-5.63%)

Barchart Exclusives

Wells Fargo Just Upgraded Seagate Stock. Here's Why. Barchart - 23 minutes ago
Seagate stock is inching higher after Wells Fargo issued a bullish research note. Here’s how high analyst Aaron Rakers believes STX shares could fly in 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.